CACIPLIQ20® belongs to the family of ReGeneraTing Agents (RGTA®), which are engineered biodegradable sugar based polymers.
CACIPLIQ20® protects extracellular matrix proteins from the inside, hence restoring the matrix architecture. It preserves the natural cellular micro-environment of the wound and the endogenous factors needed for tissue regeneration.
CACIPLIQ20® is a sterile wound healing solution.
CACIPLIQ20® is a class III CE marked Medical Device.
Applied twice a week (every 3 to 4 days), CACIPLIQ20® is a unique product which provides an easy-to-use, effective tissue regenerating solution for rapid wound healing. It is intended to improve the healing of chronic cutaneous ulcers by promoting the restoration of the extracellular matrix, with the consequent reduction in lesion induced pain.
Warnings and contraindications exist, please read the instructions.
Indications
Chronic ulcers showing no tendency to heal after 6 months of standard care, or still unhealed after 12 months:
- Pressure ulcers.
- Peripheral arterial disease (such as – Stage IV Leriche & Fontaine) ulcers.
- Diabetic ulcers (including amputation).
Improves patient comfort
- Reducing lesion induced pain
- Reducing care time
- Excellent safety record
- Simple to use
Clinical Cases for Cacipliq 20®
Our chronic wound healing product has been used up to date by more than 200 000 patients. A selection of some clinical cases of patients treated with Cacipliq 20® are presented in this section, and more are available upon request.
Please note that this document is destined to health professionals and contains graphic images.
The efficacy of CACIPLIQ20® has been highlighted by three clinical trials, and various case studies.
Please find below a selection of clinical publications of CACIPLIQ20®:
